Resolution Therapeutics - Unlocking regenerative macrophage …

The Science +. Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built …

CouponFollow Extension

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the …

yahoo.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory …

prnewswire.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024 · Edinburgh and London, UK, 3 October 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the …

resolution-tx.com

FAQs about Resolution Therapeutics - Unlocking regenerative macrophage … Coupon?

Who is resolution Therapeutics?

Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat end-stage liver disease. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. ...

Is resolution a regenerative biopharmaceutical company?

EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces it has raised £63.5 million in Series B financing. ...

Can a macrophage cell therapy platform transform patient outcomes?

Dr Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said: "The data presented at EASL further support the robust scientific and clinical evidence in our approach. Our engineered macrophage cell therapy platform has the potential to transform outcomes in a patient population with a very high unmet need. ...

Is autologous macrophage cell therapy effective?

This study provides a clinical proof-of-concept that autologous macrophage cell therapy is well-tolerated and efficacious, supporting Resolution’s mission to develop improved macrophage cell therapy products designed for commercialisation. ...

Are macrophage cell therapies safe?

An initial smaller, Phase 1 study led by Professor Forbes in 2019, called MATCH, successfully proved its safety. In 2020, Professor Forbes co-founded Resolution Therapeutics, a biotech company focused on engineering macrophage cell therapies. ...

Can macrophage cell therapy help end-stage liver cirrhosis?

A clinical trial follow-up featuring patients with end-stage liver cirrhosis shows increased survival rates in those treated with macrophage cell therapy from Edinburgh spinout Resolution Therapeutics. ...